10 results on '"Rebar RW"'
Search Results
2. A decade after the women's health initiative--the experts do agree.
- Author
-
Stuenkel CA, Gass ML, Manson JE, Lobo RA, Pal L, Rebar RW, and Hall JE
- Subjects
- Female, Humans, Menopause, Estrogen Replacement Therapy adverse effects, Women's Health
- Published
- 2012
- Full Text
- View/download PDF
3. A decade after the Women's Health Initiative--the experts do agree.
- Author
-
Stuenkel CA, Gass ML, Manson JE, Lobo RA, Pal L, Rebar RW, and Hall JE
- Subjects
- Breast Neoplasms epidemiology, Female, Humans, Middle Aged, Risk Factors, Time Factors, Venous Thromboembolism epidemiology, Estrogen Replacement Therapy adverse effects, Estrogen Replacement Therapy methods, Estrogen Replacement Therapy trends, Menopause, Women's Health trends
- Published
- 2012
- Full Text
- View/download PDF
4. Should symptomatic menopausal women be offered hormone therapy?
- Author
-
Lobo RA, Bélisle S, Creasman WT, Frankel NR, Goodman NF, Hall JE, Ivey SL, Kingsberg S, Langer R, Lehman R, McArthur DB, Montgomery-Rice V, Notelovitz M, Packin GS, Rebar RW, Rousseau M, Schenken RS, Schneider DL, Sherif K, and Wysocki S
- Subjects
- Female, Humans, Estrogen Replacement Therapy adverse effects, Menopause
- Abstract
Unlabelled: Many physicians remain uncertain about prescribing hormone therapy for symptomatic women at the onset of menopause. The American Society for Reproductive Medicine (ASRM) convened a multidisciplinary group of healthcare providers to discuss the efficacy and risks of hormone therapy for symptomatic women, and to determine whether it would be appropriate to treat women at the onset of menopause who were complaining of menopausal symptoms., Major Findings: Numerous controlled clinical trials consistently demonstrate that hormone therapy, administered via oral, transdermal, or vaginal routes, is the most effective treatment for vasomotor symptoms. Topical vaginal formulations of hormone therapy should be preferred when prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy. Data from the Women's Health Initiative indicate that the overall attributable risk of invasive breast cancer in women receiving estrogen plus progestin was 8 more cases per 10,000 women-years. No increased risk for invasive breast cancer was detected for women who never used hormone therapy in the past or for those receiving estrogen only. Hormone therapy is not effective for the treatment of cardiovascular disease and that the risk of cardiovascular disease with hormone therapy is principally in older women who are considerably postmenopause., Conclusions: Healthy symptomatic women should be offered the option of hormone therapy for menopausal symptoms. Symptom relief with hormone therapy for many younger women (at the onset of menopause) with menopausal symptoms outweighs the risks and may provide an overall improvement in quality of life. Hormone therapy should be individualized for symptomatic women. This involves tailoring the regimen and dose to individual needs.
- Published
- 2006
5. A short study in the treatment of hot flashes with buccal administration of 17-beta estradiol.
- Author
-
Gass MS, Rebar RW, Cuffie-Jackson C, Cedars MI, Lobo RA, Shoupe D, Judd HL, Buyalos RP, and Clisham PR
- Subjects
- Administration, Buccal, Adult, Aged, Aged, 80 and over, Double-Blind Method, Estradiol adverse effects, Estradiol blood, Female, Follicle Stimulating Hormone blood, Humans, Luteinizing Hormone blood, Middle Aged, Pilot Projects, Treatment Outcome, Estradiol administration & dosage, Estrogen Replacement Therapy methods, Hot Flashes drug therapy, Postmenopause
- Abstract
Objective: To assess the efficacy and safety of 17-beta estradiol buccal tablets in reducing hot flush frequency (HFF) in postmenopausal women., Methods: Estradiol buccal tablets containing 0.05, 0.1, 0.2, or 0.4 mg or placebo were administered for 28 days to 99 postmenopausal women in a randomized, double-blind study; 19 premenopausal women were studied concurrently for comparison of laboratory data. Objective and subjective assessments of HFF were obtained along with measures of estradiol, estrone, follicle-stimulating hormone (FSH), and luteinizing hormone (LH)., Results: Measurements of HFF revealed significant decreases from baseline in all estradiol groups (P < 0.01). In the 0.4 mg group, HFF decreased significantly compared to placebo (P < 0.01). All estradiol doses produced similar improvement in the vaginal maturation index. Mean serum estradiol levels increased as doses increased but were lower than in the premenopausal subjects. Mean serum FSH and LH levels decreased in all estradiol groups but not to the levels of the premenopausal subjects; the greatest decrease occurred at the two highest estradiol doses., Conclusion: A numerical dose-response relationship with hot flushes was seen in this pilot study comparing 0.05, 0.1, 0.2, and 0.4 mg buccal estradiol. Only 0.4 mg 17-beta estradiol significantly reduced the occurrence of hot flushes compared to placebo.
- Published
- 2004
- Full Text
- View/download PDF
6. Increased coronary events, HERS, and HRT: any connection?
- Author
-
Rebar RW and Archer D
- Subjects
- Aged, Clinical Trials as Topic, Estrogen Replacement Therapy methods, Estrogens administration & dosage, Female, Follow-Up Studies, Humans, Incidence, Middle Aged, Postmenopause, Progestins administration & dosage, Risk Assessment, Time Factors, Coronary Disease epidemiology, Coronary Disease etiology, Estrogen Replacement Therapy adverse effects, Estrogens adverse effects, Progestins adverse effects
- Published
- 2001
- Full Text
- View/download PDF
7. Low-dose esterified estrogens (0.3 mg/day): long-term and short-term effects on menopausal symptoms and quality of life in postmenopausal women.
- Author
-
Rebar RW, Trabal J, and Mortola J
- Subjects
- Double-Blind Method, Endometrial Hyperplasia epidemiology, Equilin adverse effects, Estrone adverse effects, Female, Hot Flashes drug therapy, Humans, Middle Aged, Placebos, Surveys and Questionnaires, Sweating, Uterine Hemorrhage epidemiology, Vaginal Diseases drug therapy, Equilin administration & dosage, Equilin analogs & derivatives, Estrogen Replacement Therapy, Estrone administration & dosage, Postmenopause, Quality of Life
- Abstract
Objective: To study the impact of low-dose unopposed esterified estrogens on menopausal symptoms and quality of life., Methods: In a long-term, 2-year, randomized, double-blind, placebo-controlled study, 204 postmenopausal women were treated with esterified estrogens 0.3 mg daily or placebo. Menopausal symptoms were assessed with a modified Kupperman index at baseline, 3, 6 and thereafter every 6 months. In a second 12-week, open-label, short-term pilot study, 25 postmenopausal women with moderate to severe vasomotor symptoms were treated with esterified estrogens 0.3 mg daily for 12 weeks. Vasomotor symptoms and quality of life were assessed using the Greene scale and Quality of Life Menopause Scale (QUALMS)., Results: In the long-term study, significant (p < 0.05) reductions in total symptom scores were observed at each time point with esterified estrogens compared with placebo. Somatic symptom scores (hot flushes, night sweats, vaginal dryness) decreased significantly (p < 0.01) in patients treated with esterified estrogens 0.3 mg compared to baseline and placebo. In the short-term, open-label pilot study, the incidence of vasomotor symptoms was significantly (p < 0.01) reduced with esterified estrogens 0.3 mg from week 4 until the study end. Significant (p < 0.05) improvements versus baseline were seen in the somatic and vasomotor/sleep domains and in the total quality-of-life score., Conclusions: Esterified estrogens 0.3 mg given daily provide adequate menopausal symptom relief and improved quality of life in postmenopausal women.
- Published
- 2000
- Full Text
- View/download PDF
8. Isoflavones and postmenopausal bone health: a viable alternative to estrogen therapy?
- Author
-
Scheiber MD and Rebar RW
- Subjects
- Aged, Animals, Bone Density physiology, Clinical Trials as Topic, Disease Models, Animal, Female, Humans, Isoflavones metabolism, Middle Aged, Rabbits, Rats, Sensitivity and Specificity, Bone Density drug effects, Estrogen Replacement Therapy methods, Isoflavones administration & dosage, Osteoporosis, Postmenopausal prevention & control
- Abstract
Objective: The rapidly growing postmenopausal population in the United States, and this population's high incidence and prevalence of osteoporosis and related morbidity and mortality herald an enormous public health burden for the coming decades. Estrogen replacement has been the mainstay of therapy for the prevention and treatment of osteoporosis in this estrogen-deficient population. However, long-term compliance with estrogen therapy generally is poor, and there are numerous concerns regarding its safety. The phytoestrogens are nonsteroidal plant-derived compounds that exhibit estrogenic activity at several sites. The isoflavones are one class of phytoestrogens derived largely from soy-based products. International popularity for menopausal therapy regimens containing isoflavones is growing rapidly. In this article, we review the existing data on isoflavones and postmenopausal bone health., Design: A review of interventional trials examining isoflavones and bone in animals and humans., Results: The data point to a reduction in bone resorption resulting from isoflavone/ipriflavone intake., Conclusions: The data on naturally occurring isoflavones are very limited but suggest that including them in the diet results in reduction in bone resorption caused by estrogen deficiency. The extensive data on ipriflavone, a synthetic isoflavone derivative, suggest that it is a useful and safe alternative to estrogen therapy in treating existing low bone mass or osteoporosis in postmenopausal women. Further studies are warranted to examine the utility of ipriflavone as a preventive agent, as well as the clinical efficacy of the naturally occurring isoflavones.
- Published
- 1999
- Full Text
- View/download PDF
9. Unanswered questions in hormonal replacement therapy.
- Author
-
Rebar RW
- Subjects
- Breast drug effects, Cardiovascular System drug effects, Climacteric drug effects, Estrogens adverse effects, Estrogens therapeutic use, Female, Humans, Progestins adverse effects, Progestins therapeutic use, Estrogen Replacement Therapy adverse effects
- Abstract
This review addresses many of the unanswered questions existing relative to the use of exogenous estrogens and progestins in postmenopausal women (PMW). The literature in the field is reviewed and summarized, with a particular effort to identify key questions of major concern. The effect of selection bias on conclusions reached from retrospective studies involving hormone replacement therapy (HRT) has not been examined. Less is actually known about the effects of progestins than estrogens. Many of the endocrine changes that occur with aging remain poorly defined. Effects of estrogens and progestins on the breast and on breast cancer are unclear. Estrogens have recognized beneficial effects and progestins have detrimental effects on lipoprotein metabolism. Estrogens also have direct effects on the vasculature and may impact on cardiovascular risk in other ways. Although estrogens are the only agents known to eliminate hot flushes, the mechanism by which flushes arise is not known. Estrogens may have ameliorating effects on mood and behavior and may improve dementia, but research in this area has been limited to date. Lastly, the preferred estrogens and progestins, their dosages and routes of administration, remain to be more completely defined.
- Published
- 1994
- Full Text
- View/download PDF
10. Gonadotropin dynamics in women receiving immediate or delayed transdermal estradiol after oophorectomy.
- Author
-
Kamel EM, Maurer SA, Hochler MG, Hoffman DI, and Rebar RW
- Subjects
- Administration, Cutaneous, Adult, Estradiol administration & dosage, Estradiol blood, Estradiol therapeutic use, Female, Humans, Middle Aged, Prospective Studies, Time Factors, Estradiol pharmacology, Estrogen Replacement Therapy, Follicle Stimulating Hormone blood, Luteinizing Hormone blood, Ovariectomy, Postoperative Care methods
- Abstract
A prospective study was performed in 24 premenopausal women to evaluate the gonadotropin dynamics of pharmacologic doses of transdermal estradiol-17 beta (E2) administered after bilateral oophorectomy. Patients were given 0.2-mg transdermal E2 patches for 2 weeks, followed by 0.1-mg patches for 4 weeks either immediately postoperatively (immediate estrogen replacement therapy [ERT]) or beginning 12-14 days after surgery (delayed ERT). Serum gonadotropins and E2 levels were measured serially, and postmenopausal symptoms were prospectively recorded. Administration of 0.2 mg transdermal E2 immediately after surgery suppressed the post-castration rise in gonadotropins for at least 4 days, but LH and FSH levels did increase to the menopausal range after 2 weeks despite continued therapy. Sustained circulating levels of E2 with transdermal E2 therapy were comparable to follicular phase values. Vasomotor symptoms were well controlled by 0.2 mg of transdermal E2 in the majority of patients during the clinical trial. There was no significant estrogen-related morbidity despite the large doses used. Two patients had skin irritation at the patch site causing discontinuation of therapy. These data suggest that large doses of transdermal E2 can suppress gonadotropin levels only for a brief interval. We were unable to demonstrate any long-term alteration in the hypothalamic-pituitary set point for sensitivity to exogenous E2.
- Published
- 1991
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.